Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients

NCT02311647 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT02311647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02311647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients
Lead sponsor
Sheba Medical Center
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2015
Completion date
February 28, 2017
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial receptivity post tamoxifen exposure